Retension Pharmaceuticals names Robert Wong chief accounting officer

Retension Pharmaceuticals, Inc. disclosed in an 8-K that its board appointed Robert Wong as Vice President, Chief Accounting Officer and Principal Accounting Officer of the company, effective November 2, 2026, following board action on October 21, 2026.¹

According to the filing, Wong, 60, has 30 years of management and controllership experience, and most recently worked as Vice President of Accounting at The Save Mart Companies, a West Coast regional grocery chain, where he oversaw accounting, finance, tax and treasury functions.¹ Before that, he served as Vice President and Chief Accounting Officer at Cytokinetics, Inc. (NASDAQ: CYTK) from 2019 to 2024, and spent 1996 to 2019 at Genentech, Inc. in roles of increasing seniority, ending as Controller and Chief Accounting Officer; Genentech became a wholly owned subsidiary of Roche Holding in 2009.¹ The filing also notes his career began as an audit manager at Ernst & Young LLP,¹ and he holds a Bachelor of Science in Business Administration from the University of California, Berkeley and is a certified public accountant.¹

Retension stated there is no arrangement or understanding with any other person tied to Wong's appointment, and no family relationship between Wong and the company's directors or executive officers.¹ The company also said Wong has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K.¹

Per the offer letter terms disclosed, Wong will receive an annual base salary of $360,000, a discretionary bonus target of 30% of base salary prorated for 2026, a $20,000 sign-on bonus contingent on employment through March 31, 2027, and a stock option to purchase 25,000 shares vesting 25% after one year and then monthly over 36 months.¹ He will also be eligible for standard executive benefits, including the company's Executive Change in Control and Severance Plan.¹